Vascular endothelial growth factor

Journal of Nara Medical Association

Volumn 55, Issue 2, 2004, Pages 63-72

  Yoshiji, Hitoshi ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Hepatocellular carcinoma; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; LIVER CELL CARCINOMA; REPRESSOR GENE; REVIEW; TUMOR VASCULARIZATION;

EID: 3042719230     PISSN: 13450069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Hlatky. L., Hahnfeldt, P and Folkman, J.: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94: 883-93, 2002.
2. Scappaticci, F. A: Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20: 3906-27, 2002.
3. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9: 653-60, 2003.
4. Folkman, J.: Tumor angiogenesis: therapeutic implications. N Engl J. Med. 285: 1182-6, 1971.
5. Fox, S. B., Gatter, K. C., and Harris, A. L.: Tumour angiogenesis. J. Pathol. 179: 232-7, 1996.
6. Boehm, T., Folkman, J., Browder, T., et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-7, 1997.
7. Griscelli, F., Li, H., Cheong, C., et al: Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. U S A 97: 6698-703., 2000.
8. Lee, C. G., Heijn, M., di Tomaso, E., et al: Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60: 5565-70., 2000.
9. Geng, L., Donnelly, E., McMahon, G., et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61: 2413-9., 2001.
10. Ferrara, N., Gerber, H. P., and LeCouter, J.: The biology of VEGF and its receptors. Nat. Med. 9: 669-76, 2003.
11. Shibuya, M.: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 26: 25-35, 2001.
12. Bruns, C. J., Liu, W., Davis, D. W., et al: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89: 488-99., 2000.
13. Saito, M., Hamasaki, M., and Shibuya, M.: Induction of tube formation by angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. Cancer Sci. 94: 782-90, 2003.
14. Soker, S., Takashima, S., Miao, H. Q., et al: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell 92: 735-45, 1998.
15. Kanno, S., Oda, N., Abe, M., et al: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-46, 2000.
16. Waltenberger, J., Claesson Welsh, L., Siegbahm, A., et al: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem 269: 26988-95, 1994.
17. Hiratsuka, S., Maru, Y., Okada, A., et al: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61: 1207-13, 2001.
18. Hiratsuka, S., Nakamura, K., Iwai, S., et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300, 2002.
19. Luttun, A., Tjwa, M., Moons, L., et al: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti Flt1. Nat. Med. 8: 831-40, 2002.
20. Skobe, M., Hawighorst, T., Jackson, D. G., et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7: 192-8, 2001.
21. White, J. D., Hewett, P. W., Kosuge, D., et al: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62: 1669-75, 2002.
22. Nagy, J. A., Masse, E. M., Herzberg, K. T., et al: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360-8, 1995
23. Yoshiji, H., Kuriyama, S., Hicklin, D. J, et al: The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33: 841-7., 2001.
24. Yancopoulos, G. D., Davis, S., Gale, N. W., et al: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-8., 2000
25. Karkkainen M J, Petrova, TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19: 5598-605., 2000.
26. Befeler, A. S., Di Bisceglie, A. M.: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-19, 2002.
27. Suzuki, K., Hayashi, N., Miyamoto, Y., et al: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56: 3004-9, 1996.
28. Yamaguchi, R., Yano, H., Iemura, A., et al: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77, 1998.
29. Gossen, M., Bujard, H.: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U S A 89: 5547-51, 1992.
30. Paulus, W., Baur, I., Boyce, F. M, et al: Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. 70: 62-7, 1996
31. Yoshiji, H., Kuriyama, S., Yoshii, J., et al: Vascular endothelial growth factor tightly regulates In vivo development of murine hepatocellular carcinoma cells. Hepatology 28: 1489-96, 1998.
32. Yoshiji, H., Kuriyama, S., Yoshii, J., et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-42, 2002.
33. Kerbel, R. S.: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-15., 2000.
34. Bergers, G., Javaherian, K., Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-12, 1999.
35. Frachon, S., Gouysse, G., Dumorti, J., et al: Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 34: 850-7., 2001.
36. Park, Y. N., Kim, Y. B., Yang, K. M., et al: Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 124: 1061-5, 2000.
37. Shiratori, Y., Imazeki, F., Moriyama, M., et al: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132: 517-24, 2000.
38. Kalluri, R. and Sukhatme, V. P.: Fibrosis and angiogenesis. Curr Opin. Nephrol. Hypertens 9: 413-8, 2000.
39. Yoshiji, H., Kuriyama, S., Yoshii, J., et al: Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347-54, 2003.
40. Yoshiji, H., Kuriyama, S., Hicklin, D. J., et al: KDR/Flk-1 is a major regulator of vascular endothelial growth factor- induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30: 1179-86, 1999.
41. Takahashi, T., Ueno, H., Shibuya, M.: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-30, 1999.
42. Yoshiji, H., Kuriyama, S., Ways, D. K., et al: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59: 4413-8, 1999.
43. Lever, A. F., Hole, D. J., Gillis, C. R., et al: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-84, 1998.
44. Yoshiji, H., Kuriyama, S., Kawata, M., et al: The angiotensin-I- converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7: 1073-8., 2001.
45. Yoshiji, H., Yoshii, J., Ikenaka, Y., et al: Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 20: 1227-31, 2002.
46. Williams, B., Baker, A. Q., Gallacher, B., et al: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25: 913-7, 1995.
47. Noguchi, R., Yoshiji, H., Kuriyama, S., et al: Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 9: 6038-45, 2003.
48. Yoshiji, H., Kuriyama, S. and Fukui, H.: Perindopril: possible use in cancer therapy. Anticancer Drugs 13: 221-8, 2002.
49. Yoshiji. H., Kuriyama, S. and Fukui, H.: Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-56, 2002.
50. Yoshiji, H., Yoshii, J., Ikenaka, Y., et al: Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 37: 22-30, 2002.
51. Losordo, D. W., Vale, P. R., Symes, J. F., et al : Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800-4, 1998.
52. Yoshiji, H., Kuriyama, S., Yoshii, J., et al: Halting the vascular endotheial growth factor and receptor interaction attenuates the liver carcinogenesis in mice. Hepatology 2004 in press.
53. Yoshiji, H., Kuriyama, S., Yoshii, J., et al: Involvement of the vascular endothelial growth factor receptor-1(VEGFR-1) in murine hepatocelluar carcinoma development. J. Hepatpol. 2004 in press.